3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Launched by 3D MEDICINES · Feb 22, 2022

Keywords

ClinConnect Summary

This clinical trial is designed to test a new medication called 3D1002, both on its own and alongside oxycodone (a common pain relief medicine), to see how well it can manage moderate to severe pain caused by cancer. Researchers want to determine if this combination can help patients feel better and improve their quality of life. The study is looking for adults aged 18 and older who have been diagnosed with cancer and are experiencing stable pain that requires ongoing treatment.

To participate in the trial, you would need to meet certain criteria, such as having a confirmed cancer diagnosis and stable pain that scores 4 or higher on a pain scale during an initial observation period. Participants will need to agree not to use any other pain medications during the study. The trial will not accept individuals with a history of certain serious health conditions or those who are pregnant or breastfeeding. If you qualify and choose to participate, you can expect to receive either the new medication or the combination treatment for a set period while being closely monitored by the research team. This could be an important opportunity to contribute to the understanding of pain management in cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject must sign the informed consent in person prior to beginning any screening procedure.
• • 2. Age ≥18, both male and female.
• • 3. Subjects with a malignant tumor confirmed by histopathology or cytology.
• • 4. Weight ≥40 kg at screening period.
• • 5. Subjects have relatively stable cancer pain and require continuous analgesic medications (estimated treatment duration ≥2 weeks), as assessed by the investigator.
• • 6. Estimated life expectancy ≥3 months.
• • 7. Subjects are willing to not use any analgesic other than those specified in the study during the study treatment period.
• • 8. ECOG PS score is 0-3.
• • 9. Have adequate organ and bone marrow function.
• • 10. The mean NRS scores per day during the washout period are ≥4.
• Exclusion Criteria:
• • 1. Known allergy to any of the active ingredients or excipients of the study drug, or have a history of allergy to other opioids or non-steroidal anti-inflammatory drugs (NSAIDs) and their related ingredients.
• • 2. Have a persistent pain resulted from other medical conditions or unknown causes.
• • 3. Subjects presenting with emergency symptoms such as intestinal obstruction/perforation, spinal cord compression, epidural metastasis, or fracture.
• • 4. Subjects with known active/symptomatic central nervous system metastasis and/or cancerous meningitis.
• • 5. Subjects plan to be treated with \>10 mg/ day of prednisone or equivalent systemic corticosteroid during the study period.
• • 6. Have a history of gastrointestinal bleeding or perforation.
• • 7. Have a positive result of fecal occult blood test during screening period.
• • 8. Have a history of serious cardiovascular diseases.
• • 9. Have a history of an acute ischemic or hemorrhagic stroke within 6 months prior to screening.
• • 10. Have a history of significant psychiatric disorders, such as schizophrenia and depression.
• • 11. Subjects plan to receive radiotherapy, surgery, or a new regimen of systemic antitumor agents during the study treatment period (D1-D15).
• • 12. Subjects have a history of alcohol abuse or drug abuse including opioids.
• • 13. Subjects have significant opioid contraindications.
• • 14. Pregnant or lactating women.
• • 15. Subjects with other diseases that affect the oral administration or absorption of drugs.
• • 16. Subjects are currently participating in another clinical study.
• • 17. Other conditions deemed by the investigator to be inappropriate for participation in this study, such as poor compliance.